Job Opportunities API

The Public Ledger of Openings

← Back to the ledger

Psychiatrist - Bryker Woods (Greenbrook)

careers-neuronetics
Companycareers-neuronetics
CategoryHealthcare
LocationAustin, TX
Remote
EmploymentNot stated
LevelNot stated
SalaryNot stated by the employer
First seen4 Aug 2026 (the employer did not state a posting date)
Last verified12 Aug 2026
SourceEmployer ATS (rippling)
Applications are handled by the employer, not by us.Apply on the employer's site →
Description
Greenbrook Mental Wellness Centers, a subsidiary of Neuronetics, Inc., is seeking a Board Certified or Board Eligible Psychiatrist to provide onsite oversight of Transcranial Magnetic Stimulation (TMS) treatments and support the growth of our Spravato® (esketamine) program in Austin, TX. Why Join Us? • Flexible schedule • No nights, weekends, or on-call responsibilities • Competitive compensation • TMS certification and training provided • Opportunity to expand your expertise in interventional psychiatry • Collaborative clinical and operational support team • Make a meaningful impact on patients with treatment-resistant depression and other mental health disorders Qualifications • MD or DO • Board Certified or Board Eligible • Active Texas medical license (or ability to obtain) • DEA registration (or ability to obtain) About Greenbrook Greenbrook Mental Wellness Centers, a subsidiary of Neuronetics, Inc. , is a leading provider of TMS and Spravato® therapies, delivering innovative, evidence-based treatments for depression, OCD, and other mental health conditions. Through a nationwide network of treatment centers, Greenbrook is helping patients find relief when traditional treatments have not been successful. Join us in transforming mental health care and improving lives. Learn More • Provider Information: Greenbrook for Providers | TMS Therapy & Esketamine • Patient Stories: Patient Stories | Greenbrook • Our Why: https://youtu.be/yrr-wlFftT0 GBSP25 About Us Neuronetics, Inc. is a leading mental healthcare company, now encompassing Greenbrook TMS as a subsidiary. This strategic acquisition unites Neuronetics' innovative NeuroStar® Advanced Therapy (TMS) technology with Greenbrook's extensive network of over 95 U.S. treatment centers. The combined company provides FDA-cleared NeuroStar® TMS and Spravato® treatments for major depressive disorder (MDD) and treatment-resistant depression. With a strengthened nationwide footprint, Neuronetics is dedicated to significantly expanding patient access to these crucial therapies, integrating advanced technology with established clinical expertise to improve patient outcomes and drive growth within the mental health sector.